Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Osteonecrosis of the Jaw in a Patient on Denosumab

Open access
Aghaloo, Tara L., Felsenfeld, Alan L., Tetradis, Sotirios·2010·Journal of Oral and Maxillofacial Surgery

Abstract

Osteonecrosis of the jaws (ONJ) clinically presents as exposed, necrotic bone in the maxilla or mandible of at least eight week duration, with or without the presence of pain, infection, or previous trauma in a patient who has not received radiation to the jaws (1–3). Although necrotic bone exposure has been reported in the jaws of a variety of patients not receiving bisphosphonates (BPs;4–9), the number of BP related ONJ cases has continued to steadily increase since the first report in 2003 (10). To date, a direct causal relationship between BP use and ONJ has not been established (11,12). However, many retrospective and prospective analyses have identified cases of ONJ where BP therapy, especially the more potent intravenous preparations, was the only consistent variable, strongly suggesting that BPs play a significant role in ONJ pathophysiology (13–24). Potential mechanisms underlying bisphosphonate related osteonecrosis of the jaws (BRONJ) pathophysiology have generated great debate in the literature (25,26). It is not surprising that many hypotheses attempt to explain the unique localization of BRONJ exclusively to the jaws, including altered bone remodeling, angiogenesis inhibition, constant microtrauma, soft tissue BP toxicity, and bacterial infection (15,18,25,27–29). Importantly, ONJ incidence correlation with BP potency suggests that inhibition of osteoclast function and differentiation might be a key factor in the pathophysiology of the disease. Currently other inhibitors of osteoclast differentiation and function are entering the pharmacologic armamentarium for the treatment of diseases with increased bone turnover. The association of these new therapies with ONJ is uncertain. We report a case of ONJ in a patient receiving Denosumab, a human RANKL monoclonal antibody currently in clinical trials for the treatment of osteoporosis, primary and metastatic bone cancer, giant cell tumor, and rheumatoid arthritis (30–33).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.joms.2009.10.010

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

See all 275

Metadata

Authors
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S.
Venue
Journal of Oral and Maxillofacial Surgery
Publisher
Elsevier BV
Published
2010-05
Volume
68
Issue
5
Pages
959-963
ISSN
0278-2391 (ISSN-L)
OpenAlex
W2090174147
Cited by
275
References
56
FWCI
11.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osteonecrosis of the Jaw in a Patient on Denosumab. https://app.cochat.ai/papers/10.1016/j.joms.2009.10.010
The paper
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S. (2010). Osteonecrosis of the Jaw in a Patient on Denosumab. Journal of Oral and Maxillofacial Surgery. https://doi.org/10.1016/j.joms.2009.10.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.